Investor Presentaiton
Strong business momentum
Diversified portfolio growth
Efficient compounding engine
Sustainable long-term growth
Participating in most important waves of biopharma innovation
Rituxan - blood cancer/immunology
Neupogen/Neulasta - supportive cancer care
Thalomid - blood cancer
Truvada - HIV
Humira - immunology
Remicade - immunology
Lyrica - nerve pain
Januvia - diabetes
Tecfidera/Tysabri - MS
Imbruvica - blood cancer
Kalydeco - cystic fibrosis
Xtandi - prostate cancer
Next exciting waves of
biopharma innovation
Trikafta - cystic fibrosis
Tremfya - immunology
Cabometyx - kidney cancer
Entyvio - gastrointestinal
Evrysdi - spinal muscular atrophy
Nurtec/Emgality - migraine
ROYALTY PHARMA MS: Multiple sclerosis
99
99View entire presentation